BRIEF—The Alliance for Regenerative Medicine appoints new chief executive

The Alliance for Regenerative Medicine (ARM), the international advocacy group representing the cell and gene therapy sector, has appointed Timothy Hunt as its next chief executive.

Mr Hunt was most recently the chief culture and corporate affairs officer at Xilio Therapeutics, a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer. Prior to that, he was the chief corporate affairs officer at CRISPR gene-editing pioneer Editas Medicine.

Mr Hunt will succeed Janet Lynch Lambert, who also served on the board’s search committee.

Emile Nuwaysir, chairman of the ARM board and search committee, said: "Tim’s two decades of experience advocating for biotechnology companies, knowledge of the key issues facing the cell and gene therapy field, and expertise in leading teams make him the ideal choice to guide ARM in building the future of medicine. Tim has a deep philosophy of engagement with major stakeholders that will support ARM members and help bring cell and gene therapies into mainstream medical practice."